CIP2A and lung carcinoma: Previous studies have suggested potential mechanisms to explain the erlotinib activities in EGFR-wt lung cancers, such as EGFR copy numbers [34], mutations in other exons of the EGFR gene [35], cancerous inhibitor of protein phosphatase 2A (CIP2A) pathway [36] and VeriStrat status [37].